Approaches to Dosing TKIs in Patients with Advanced RCC

Based on updated data from the TRUST-1 trial, taletrectinib is now approved by the FDA for patients with TKI-naive ROS1+ NSCLC.

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.

Poster presentations at SOHO 2026 may inform multiple myeloma practice across the newly diagnosed and relapsed/refractory settings.

The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.

The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.